What is cutaneous Pseudolymphoma?
Cutaneous pseudolymphoma refers to a heterogeneous group of benign reactive T- or B-cell lymphoproliferative processes of diverse causes that simulate cutaneous lymphomas clinically and/or histologically.
How common is pseudolymphoma?
Although drug-induced pseudolymphoma remains a rare disorder, more than 100 individual cases have been reported in the literature worldwide.
Can pseudolymphoma turn into lymphoma?
Although rare, reports of cutaneous B-cell pseudolymphoma evolving into B-cell lymphoma have been described. In one study of 4 cases, transformation of 1 case of pseudolymphoma into a large B-cell lymphoma was identified, similar to our patient [7].
What is cutaneous lymphoid hyperplasia?
Cutaneous lymphoid hyperplasia (CLH) is considered a benign lymphoid reactive process that results from various antigenic stimuli and may have potential for progression to overt lymphoma. CLH lesions may closely resemble lymphoma both clinically and histologically.
What causes Pseudolymphoma?
Pseudolymphoma, also called as cutaneous lymphoid hyperplasia, is a skin lesion having lymphomatous appearance mimicking lymphoma that results from known or unknown stimulus like insect bites, vaccination, trauma, folliculitis, drugs, jewelry, and contactants.
What drugs cause Pseudolymphoma?
Anticonvulsants, typically phenytoin and carbamazepine, are the most frequent cause of drug-induced pseudolymphoma.
Is pseudolymphoma curable?
Cases of cutaneous pseudolymphoma documented to occur as a result of infection should be appropriately treated. In idiopathic cases of cutaneous pseudolymphoma, treatment is not mandatory. Cures may be effected via surgical removal, cryosurgery, or local irradiation.
Is pseudolymphoma itchy?
Patients with B-cell pattern pseudolymphoma present with a nodule or a group of discrete nodules, usually with minimal associated symptoms. Occasionally, patients present with pruritus or pain.
How is cutaneous lymphoid hyperplasia treated?
Historically, CLH was treated with a combination of antibiotics, topical or intralesional corticosteroids, and/or localized radiotherapy. Rituximab, a monoclonal antibody that targets the CD20 marker on B cells, is an effective and well-reported treatment for PCBCL.
